Phaseline

Targets › CHEK2

CHEK2 (Serine/threonine-protein kinase Chk2): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 2; Oncology; next expected readout May 2027.

Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest, activation of DNA repair and apoptosis in response to the presence of DNA double-strand breaks. May also negatively regulate cell cycle progression during unperturbed cell cycles. (UniProt, O96017)

Open in Phaseline: the race on CHEK2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Acrivon TherapeuticsPrexasertib (ACR-368)
Serine/threonine-protein kinase Chk1 inhibitor; Serine/threonine-protein kinase Chk2 inhibitor
CHEK1, CHEK2Phase 2Endometrial Adenocarcinoma; Head and Neck Squamous Cell CarcinomaMay 2027

Conditions

Endometrial Adenocarcinoma (1) Head and Neck Squamous Cell Carcinoma (1)

Modalities

small molecule (1)

Companies

Acrivon Therapeutics (1)

Related targets

CHEK1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.